Aydan ERATALAY*, Filiz ÖNER*o

*Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Biotechnology, 06100, Sihhiye, Ankara, TURKEY.
oCorrespondence

Summary:
New vacciens have some advantages due to their purity and safety characteristics, over conventional vaccines, but preventive properties need to be progressed.This can be achieved by using some materials or carriers called adjuvants which helps to increase immune response to an antigen.
There are two adjuvant formulations which have been used since 1950’s.One of them is mineral oil emulsions including micobacteria or not,second one is gel or suspension formulations of aluminium salts.Studies on new adjuvants or adjuvant carriers are increasing due to the side effects of conventional adjuvants
Recently new adjuvants and carrier systems for modern vaccines are attracting more attention because of the poor immunogenicity of pure subunit or synthetic recombinant antigens and problems with aluminium based adjuvants.
New adjuvants have to be nontoxic,noncarcinogenic,must not cause local and systemic reactions and they have to provide long term immune protection with small number of application.
In this article adjuvant carrier systems and materials used for subunit and recombinant
DNA derived vaccines are viewed.